nogapendekin alfa inbakicept
nogapendekin alfa inbakicept: sourced relationships with 1 company · 28 clinical trials tracked.
nogapendekin alfa inbakicept evidence translation
What we can confirm
28 tracked trials
What it means
What to watch
Prepared research question
How could nogapendekin alfa inbakicept → IBRX affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (2)
| Company | Dated record stage |
|---|---|
| ImmunityBio, Inc. (IBRX) | Phase 3 |
| ImmunityBio, Inc. (IBRX) Pancreatic Cancer; NSCLC Stage IV; Bladder Cancer | Phase 3 |
Clinical Trial Registry Records (28)showing 10 most recent
ResQ117EX-ALC: Expanded Access Use of Nogapendekin-alfa Inbakicept in the Reversal and Maintenance of Absolute Lymphocyte Count (ALC) for the Treatment of Lymphopenia Induced by Chemotherapy, Immunotherapy, and/or Radiation Therapy
Open-Label, Single-Arm, Phase 1b Clinical Trial of NAI Plus Pembrolizumab With Short Course of Enfortumab Vedotin in Treatment-Naïve Participants With Metastatic Urothelial Carcinoma
Primary endpoint: Assess the safety and tolerability of the treatment regimen (NAI, EV, and pembrolizumab).
A Phase Ib Study Evaluating the Safety and Tolerability of Sipuleucel-T (Sip-T) in Combination With N-803 in Patients With Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Primary endpoint: Frequency of dose-limiting toxicities (Cohort 1 only)
Phase 2a, Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Safety and Efficacy of Nogapendekin Alfa Inbakicept (NAI) Plus Standard of Care (SOC) Compared to SOC Alone in Critically Ill Adults With Sepsis
Primary endpoint: 28-day all-cause mortality rate
Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer
Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Open-Label, Single-Arm Phase 2 Study Of Nogapendekin Alfa Inbakicept, PD-L1 T-HaNK, And Bevacizumab And Randomized Phase 2B Study Of Nogapendekin Alfa Inbakicept, Bevacizumab, And Tumor Treatment Fields With Or Without PD-L1 T-HaNK In Participants With Recurrent Or Progressive Glioblastoma
Primary endpoint: Progression-Free Survival (PFS)
A Phase Ib/II, Single-Center, Open-Label Study of First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (FLINN)
Primary endpoint: Progression-free survival (PFS) (Phase Ib acceptable dose participants and Phase II participants)
Phase 2, Randomized, Open-Label Clinical Trial Evaluating Nogapendekin Alfa Inbakicept in Combination With Standard of Care Versus Standard of Care Alone in Critically Ill Adults With Sepsis and Persistent Lymphopenia
Primary endpoint: 28-day all-cause mortality rate
Phase 3 Randomized, Blinded, Placebo-Controlled Study Evaluating Nogapendekin Alfa Inbakicept and iNKT Cells In Critically Ill Adults With Severe Community-Acquired Pneumonia With or Without Sepsis/Acute Respiratory Distress Syndrome
Primary endpoint: 28-day all-cause mortality
Open-Label, Phase 2 Chemotherapy-Free Study of CD19 t-haNK and NAI in Combination With Rituximab in Participants With Relapsed/Refractory B-Cell Indolent Non-Hodgkin Lymphoma
Primary endpoint: ORR in accordance with Lymphoma Response to Immunomodulatory Therapy Criteria (LYRIC)
Frequently asked questions
Which companies have sourced relationships with nogapendekin alfa inbakicept?
nogapendekin alfa inbakicept has dated SEC/FDA relationship records for ImmunityBio, Inc..
How many clinical trials involve nogapendekin alfa inbakicept?
BioSniper tracks 28 clinical trials involving nogapendekin alfa inbakicept.